Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 449Carcinoma, Non-Small-Cell Lung 372Neoplasms 349Prostatic Neoplasms 285Colorectal Neoplasms 273Multiple Myeloma 211Lung Neoplasms 201Neoplasm Metastasis 185Leukemia, Myeloid, Acute 163Ovarian Neoplasms 159Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 140Melanoma 131Recurrence 108Glioblastoma 105Head and Neck Neoplasms 103Carcinoma, Renal Cell 103Endometrial Neoplasms 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Lymphoma, Non-Hodgkin 95Stomach Neoplasms 94Carcinoma, Hepatocellular 94Lymphoma 93Triple Negative Breast Neoplasms 92Brain Neoplasms 90Uterine Cervical Neoplasms 86Lymphoma, Large B-Cell, Diffuse 81Glioma 79Urinary Bladder Neoplasms 78Sarcoma 78

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrial Serous Adenocarcinoma × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡